1. Home
  2. GCV vs CRDF Comparison

GCV vs CRDF Comparison

Compare GCV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Convertible and Income Securities Fund Inc. (The)

GCV

Gabelli Convertible and Income Securities Fund Inc. (The)

SELL

Current Price

$3.70

Market Cap

77.8M

Sector

Finance

ML Signal

SELL

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GCV
CRDF
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.8M
67.1M
IPO Year
1994
2012

Fundamental Metrics

Financial Performance
Metric
GCV
CRDF
Price
$3.70
$0.87
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $5.14
AVG Volume (30 Days)
59.5K
★ 1.0M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ N/A
N/A
Revenue
N/A
★ $365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$3.50
$0.71
52 Week High
$4.80
$3.31

Technical Indicators

Market Signals
Indicator
GCV
CRDF
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GCV
CRDF

About GCV Gabelli Convertible and Income Securities Fund Inc. (The)

GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive, and others. All the operation of the group is operated through the regions of the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: